Which biomarker tests should a patient with non-small celllung cancer receive?
Predictive biomarker testing aims to match patients with the most appropriate treatment for their tumour. This fact sheet describes the different biomarker tests recommended in advanced non-small cell lung cancer (NSCLC).
Emerging biomarkers under investigation for use in NSCLC
Research efforts are currently underway to develop the next generation of biomarkers to more effectively identify the patients most likely to benefit from particular therapies. This fact sheet describes some of the promising emerging biomarkers in NSCLC, such as tumour mutational burden, inflammatory gene signatures, immunohistochemistry-based markers and circulating tumour DNA.
Programmed cell death ligand-1 (PD-L1) testing is recommended in all tumour samples from patients with advanced/metastatic NSCLC. Further, anti-PD-L1 immunotherapy has been associated with clinical benefit in patients with NSCLC. This fact sheet explains the importance of PD-L1 testing in NSCLC and treatment decision implications.
In order to carry out PD-L1 testing, appropriate samples are required; the way in which these samples are obtained and processed can impact the success of PD-L1 testing. This fact sheet provides an overview of the different samples appropriate for PD-L1 testing in lung cancer.
The American Society of Clinical Oncology (ASCO) Clinical Practice Guidelines on NSCLC contains expert recommendations for the systemic therapy for Stage IV NSCLC.
To view the latest ASCO Clinical Practice Guideline on NSCLC, click here.
The ESMO Clinical Practice Guidelines on Metastatic NSCLC are a set of recommendations derived from recent studies and analyses that advise on the treatment and management of advanced/metastatic NSCLC.
To view the latest ESMO Clinical Practice Guidelines on Metastatic NSCLC,click here.
Canadian Association of Pathologists-Association Canadienne Des Pathologistes
The Canadian Association of Pathologistsand Association Canadienne Des Pathologistes (ACP) jointly proposed a guideline on PD-L1 biomarker testing for patient selection in immune-oncology.
To view the Canadian Association of Pathologists-ACP guidelines, click here.
National Comprehensive Cancer Network
The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for NSCLC is a series of recommendations for the risk assessment, evaluation and treatment of patients with NSCLC.
To view the latest NCCN Clinical Practice Guidelines for NSCLC, click here.
Chinese Society of Clinical Oncology-European Society for Medical Oncology
The Chinese Society of Clinical Oncology (CSCO) and European Society for Medical Oncology (ESMO) convened a special set of Pan-Asia Clinical Practice Guidelines for the diagnosis, treatment and follow-up of metastatic NSCLC. Adapted from the ESMO guidelines, this Pan-Asian version has also been endorsed by the Japanese Society of Medical Oncology, Korean Society of Medical Oncology, Malaysian Oncological Society, Singapore Society of Oncology and the Taiwan Oncology Society.
To view the latest CSCO-ESMO Clinical Practice Guidelines for the management of metastatic NSCLC, click here.
Spanish Society of Medical Oncology-Spanish Society of Pathology
The Spanish Society of Medical Oncology (SEOM)-Spanish Society of Pathology (SEAP) is a joint effort to create a set of guidelines on biomarker testing in patient with advanced NSCLC based on current evidence.
To view the latest SEOM-SEAP guidelines for predictive biomarkers testing in advanced NSCLC, click here.
College of American Pathologists-International Association for the Study of Lung Cancer-Association for Molecular Pathology
The College of American Pathologists (CAP)-International Association for the Study of Lung Cancer (IASLC)-Association for Molecular Pathology (AMP) collectively created a molecular testing guideline for the selection of lung cancer patients for the treatment with targeted tyrosine kinase inhibitors.
To view the latest CAP-IASLC-AMP guideline, click here.